KIMBERLY AUCI: Open Payments
NPI 1518741149 · WINSTON SALEM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$745 in 34 payments from 14 companies in 2025. Trend: 2023 $99 · 2024 $981 · 2025 $745
Food & beverage: $745
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $98 |
| Madrigal Pharmaceuticals | 3 | $71 |
| Phathom Pharmaceuticals, Inc. | 4 | $70 |
| Janssen Biotech, Inc. | 2 | $61 |
| PFIZER INC. | 2 | $58 |
| ABBVIE INC. | 3 | $58 |
| Organon LLC | 2 | $47 |
| Gilead Sciences, Inc. | 2 | $44 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
Products named: OMVOH, REZDIFFRA, VOQUEZNA, TREMFYA, XELJANZ, EOHILIA, ENTYVIO, SKYRIZI.
Industry payments across NC — which companies pay providers there.
